Bimekizumab Versus Secukinumab Continuous Maintenance of PASI 90 and PASI 100 Responses through One Year in Patients with Moderate to Severe Plaque Psoriasis: Post-HOC Results from the BE RADIANT Phase 3b Trial. J of Skin [Internet]. 2024 Mar. 18 [cited 2026 Apr. 18];8(2):s403. Available from: https://skin.dermsquared.com/skin/article/view/2731